Home>Topics>Companies>King Pharmaceuticals

King Pharmaceuticals KG

  1. All
  2. Commentary
  3. Headlines
    1. Prozac Nation, Street Version

      Headlines

      Fri, 25 Jul 2014

      sessions, expanded 49%. During the conference call, management mentioned that contracts with Novartis NVS and King Pharmaceuticals KG have started contributing to this segment. Revenues from the prepackaged medications segment, which accounts

    2. Covidien to Spin Out Pharmaceutical Business

      Commentary

      Thu, 15 Dec 2011

      based on our review of some of its peers, such as Endo Pharmaceuticals ENDP, as well as the recent acquisition of King Pharmaceuticals by Pfizer PFE and Bristol-Myers Squibb's BMY sale of its imaging business (which included branded Cardiolite

    3. Diamond Hill Small Cap Fund First Quarter Commentary

      Headlines

      Tue, 24 May 2011

      deals for food producer Del Monte Foods and drug maker King Pharmaceuticals closed. Del Monte was taken private by a KKR led consortium for $19 cash per share and King was acquired by Pfizer, Inc. for $14.25 per share

    4. Diamond Hill Small-Mid Cap Fourth Quarter Commentary

      Headlines

      Wed, 2 Feb 2011

      the health care sector, drug manufacturer King Pharmaceuticals , Inc. ( KG ) and medical diagnostic company Myriad Genetics ..... provided the largest contribution to return. King Pharmaceuticals agreed to be purchased by Pfizer at $14

    5. Diamond Hill Small Cap Fourth Quarter Commentary

      Headlines

      Tue, 1 Feb 2011

      contributors to performance included drug manufacturer King Pharmaceuticals , Inc. ( KG ) and semiconductor testing company Verigy Ltd (VRGY). King Pharmaceuticals agreed to be purchased by Pfizer at $14

    6. Pfizer's Acquisition of King Pharmaceuticals Should Wrap Up in 1Q

      Commentary

      Mon, 24 Jan 2011

      conditions, we expect the purchase of King Pharmaceuticals KG by Pfizer PFE to wind up by the ..... attractive premium to what we think King is worth on a stand-alone basis ..... synergies by the end of 2013. With King spending close to $550 million

    7. Kindler Resigns Unexpectedly, Pfizer Appoints Read as New CEO

      Commentary

      Mon, 6 Dec 2010

      While we continue to project organic earnings slightly below this guidance, another acquisition similar to King Pharmaceuticals KG could boost our estimates in line with management's guidance. We expect that Read will likely lead the company

    8. Pfizer Acquires King Pharmaceuticals

      Commentary

      Tue, 12 Oct 2010

      PFE announced the acquisition of King Pharmaceuticals KG for $3.6 billion or $14.25 per share, a 40% premium to King 's closing price on Oct. 11 ..... our $9 fair value estimate for King , we believe expected cost and

    9. Maintaining King's Fair Value

      Commentary

      Thu, 6 Aug 2009

      maintaining our fair value estimate for King Pharmaceuticals KG following a mediocre second quarter ..... our view. On the positive side, King has significantly reduced the costs of the Alpharma organization. King 's stock price will depend heavily

    10. King Pharma Reports Poor 1Q

      Commentary

      Mon, 11 May 2009

      reduce our fair value estimate for King Pharmaceuticals KG following a poor first-quarter ..... seamless as we had anticipated. King 's Animal Health segment (formerly ..... difficult economic environment. The King side of the business performed

    « Prev12345Next »
    Content Partners